Clinical presentation of GSD3 is similar to GSD1 in some regards with hypertriglyceridemia, hypoglycemia, hyperuricemia, hepatomegaly, etc. Data from the UKBiobank do not show moderate hypertriglyceridemia in heterozygous carriers of loss-of-function AGL genetic variants. This evidence concerns the gene AGL and hypertriglyceridemia.